133 related articles for article (PubMed ID: 26964858)
41. Receptor-targeted liposome-peptide nanocomplexes for siRNA delivery.
Tagalakis AD; He L; Saraiva L; Gustafsson KT; Hart SL
Biomaterials; 2011 Sep; 32(26):6302-15. PubMed ID: 21624650
[TBL] [Abstract][Full Text] [Related]
42. Inhibition of replication of hepatitis B virus in transgenic mice following administration of hepatotropic lipoplexes containing guanidinopropyl-modified siRNAs.
Marimani MD; Ely A; Buff MC; Bernhardt S; Engels JW; Scherman D; Escriou V; Arbuthnot P
J Control Release; 2015 Jul; 209():198-206. PubMed ID: 25937322
[TBL] [Abstract][Full Text] [Related]
43. siRNA delivery by a transferrin-associated lipid-based vector: a non-viral strategy to mediate gene silencing.
Cardoso AL; Simões S; de Almeida LP; Pelisek J; Culmsee C; Wagner E; Pedroso de Lima MC
J Gene Med; 2007 Mar; 9(3):170-83. PubMed ID: 17351968
[TBL] [Abstract][Full Text] [Related]
44. Structure and gene silencing activities of monovalent and pentavalent cationic lipid vectors complexed with siRNA.
Bouxsein NF; McAllister CS; Ewert KK; Samuel CE; Safinya CR
Biochemistry; 2007 Apr; 46(16):4785-92. PubMed ID: 17391006
[TBL] [Abstract][Full Text] [Related]
45. Cell Type-Specific Delivery of RNAi by Ligand-Functionalized Curdlan Nanoparticles: Balancing the Receptor Mediation and the Charge Motivation.
Wu Y; Cai J; Han J; Baigude H
ACS Appl Mater Interfaces; 2015 Sep; 7(38):21521-8. PubMed ID: 26345600
[TBL] [Abstract][Full Text] [Related]
46. Target-specific gene silencing of layer-by-layer assembled gold-cysteamine/siRNA/PEI/HA nanocomplex.
Lee MY; Park SJ; Park K; Kim KS; Lee H; Hahn SK
ACS Nano; 2011 Aug; 5(8):6138-47. PubMed ID: 21739990
[TBL] [Abstract][Full Text] [Related]
47. Efficient systemic delivery of siRNA to the mouse liver by pegylated lipopolymer.
Liu J; Van S; Ma N; Yu L
Int J Pharm; 2012 May; 427(1):58-63. PubMed ID: 22100515
[TBL] [Abstract][Full Text] [Related]
48. Small-interfering RNA (siRNA)-based functional micro- and nanostructures for efficient and selective gene silencing.
Lee SH; Chung BH; Park TG; Nam YS; Mok H
Acc Chem Res; 2012 Jul; 45(7):1014-25. PubMed ID: 22413937
[TBL] [Abstract][Full Text] [Related]
49. Monodispersed brush-like conjugated polyelectrolyte nanoparticles with efficient and visualized siRNA delivery for gene silencing.
Jiang R; Lu X; Yang M; Deng W; Fan Q; Huang W
Biomacromolecules; 2013 Oct; 14(10):3643-52. PubMed ID: 24040909
[TBL] [Abstract][Full Text] [Related]
50. RNA interference-mediated gene silencing of pleiotrophin through polyethylenimine-complexed small interfering RNAs in vivo exerts antitumoral effects in glioblastoma xenografts.
Grzelinski M; Urban-Klein B; Martens T; Lamszus K; Bakowsky U; Höbel S; Czubayko F; Aigner A
Hum Gene Ther; 2006 Jul; 17(7):751-66. PubMed ID: 16839274
[TBL] [Abstract][Full Text] [Related]
51. The potential and advances in RNAi therapy: chemical and structural modifications of siRNA molecules and use of biocompatible nanocarriers.
Joo MK; Yhee JY; Kim SH; Kim K
J Control Release; 2014 Nov; 193():113-21. PubMed ID: 24862319
[TBL] [Abstract][Full Text] [Related]
52. Biomaterials in siRNA Delivery: A Comprehensive Review.
Ho W; Zhang XQ; Xu X
Adv Healthc Mater; 2016 Nov; 5(21):2715-2731. PubMed ID: 27700013
[TBL] [Abstract][Full Text] [Related]
53. Mesoporous silicon particles for sustained gene silencing.
Hasan N; Mann A; Ferrari M; Tanaka T
Methods Mol Biol; 2013; 1049():481-93. PubMed ID: 23913239
[TBL] [Abstract][Full Text] [Related]
54. Nonendocytic delivery of lipoplex nanoparticles into living cells using nanochannel electroporation.
Boukany PE; Wu Y; Zhao X; Kwak KJ; Glazer PJ; Leong K; Lee LJ
Adv Healthc Mater; 2014 May; 3(5):682-9. PubMed ID: 23996973
[TBL] [Abstract][Full Text] [Related]
55. In Vivo Delivery of RNAi by Reducible Interfering Nanoparticles (iNOPs).
Baigude H; Su J; McCarroll J; Rana TM
ACS Med Chem Lett; 2013 Aug; 4(8):720-723. PubMed ID: 24319542
[TBL] [Abstract][Full Text] [Related]
56. Endosomolytic bioreducible poly(amido amine disulfide) polymer conjugates for the in vivo systemic delivery of siRNA therapeutics.
Parmar RG; Busuek M; Walsh ES; Leander KR; Howell BJ; Sepp-Lorenzino L; Kemp E; Crocker LS; Leone A; Kochansky CJ; Carr BA; Garbaccio RM; Colletti SL; Wang W
Bioconjug Chem; 2013 Apr; 24(4):640-7. PubMed ID: 23496378
[TBL] [Abstract][Full Text] [Related]
57. Dynamic PolyConjugates for targeted in vivo delivery of siRNA to hepatocytes.
Rozema DB; Lewis DL; Wakefield DH; Wong SC; Klein JJ; Roesch PL; Bertin SL; Reppen TW; Chu Q; Blokhin AV; Hagstrom JE; Wolff JA
Proc Natl Acad Sci U S A; 2007 Aug; 104(32):12982-7. PubMed ID: 17652171
[TBL] [Abstract][Full Text] [Related]
58. Efficient reduction of serum cholesterol by combining a liver-targeted gene delivery system with chemically modified apolipoprotein B siRNA.
Kang JH; Tachibana Y; Obika S; Harada-Shiba M; Yamaoka T
J Control Release; 2012 Oct; 163(2):119-24. PubMed ID: 22974833
[TBL] [Abstract][Full Text] [Related]
59. Liver target delivery of small interfering RNA to the HCV gene by lactosylated cationic liposome.
Watanabe T; Umehara T; Yasui F; Nakagawa S; Yano J; Ohgi T; Sonoke S; Satoh K; Inoue K; Yoshiba M; Kohara M
J Hepatol; 2007 Dec; 47(6):744-50. PubMed ID: 17822798
[TBL] [Abstract][Full Text] [Related]
60. Biodegradable amphiphilic poly(ethylene oxide)-block-polyesters with grafted polyamines as supramolecular nanocarriers for efficient siRNA delivery.
Xiong XB; Uludağ H; Lavasanifar A
Biomaterials; 2009 Jan; 30(2):242-53. PubMed ID: 18838158
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
